Top

Clinical and Translational Oncology

Published in:

01-08-2020 | Omeprazole | Research Article

Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review

Authors: D. Viñal, N. Rodriguez-Salas, P. Perez-Wert, O. Higuera, I. Ghanem, J. Feliu

Published in: Clinical and Translational Oncology | Issue 8/2020

Abstract

Background

Capectiabine is an oral antineoplastic drug used in multiple malignancies. Proton pump inhibitors (PPI) have been proven to interact with other oral antineoplastic agents. In this systematic review we will summarize the clinical evidence on the efficacy of capecitabine when used concomitantly with PPI.

Materials and methods

We performed a systematic literature search on the main databases up to November 2019.

Results

Nine studies met our inclusion criteria: 8 retrospective studies and 1 phase II clinical trial. Patients with colorectal, breast and gastroesophageal were represented. Four out of the 9 studies reported a shorter efficacy outcome in uni- or multivariate analysis when capecitabine was taken concomitantly with PPI than alone.

Conclusions

Up to date, the clinical evidence reported on the use of capecitabine concomitantly with PPI is scarce and shows conflicting results. While awaiting further data, avoiding misuse of PPI in cancer patients taking capecitabine is recommended.

Capecitabine (package insert). San Francisco, CA: Genentech USA Inc; 2016.

Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–81.CrossRef

Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697–710. https://doi.org/10.1038/nrgastro.2017.117.CrossRefPubMed

Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277–305.CrossRef

Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018;11(11):1123–34. https://doi.org/10.1080/17512433.2018.1531703.CrossRefPubMed

Smelick GS, Heffron TP, Chu L, Dean B. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug–drug interaction potential for molecular targeted agents in clinical development. Mol Pharm. 2013;10(11):4055–62. https://doi.org/10.1021/mp400403s.CrossRefPubMed

Hussaarts KGAM, Veerman GDM, Jansman FGA, et al. Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol. 2019;11:1758835918818347. https://doi.org/10.1177/1758835918818347.CrossRefPubMedPubMedCentral

Cheng V, Lemos M, Hunter N, Badry N, Lemos J. Concomitant use of capecitabine and proton pump inhibitors—is it safe? J Oncol Pharm Pract. 2019;25(7):1705–11. https://doi.org/10.1177/1078155219846952.CrossRefPubMed

MICROMEDEX 2.0 Drug Interactions (database on the Internet). Capecitabine. Truven Health Analytics, updated periodically. www.micromedexsolutions.com. Accessed 1 Dec 2017.

10.

Lexicomp Online: interactions (database on the Internet). Capecitabine. Lexi-Comp.

11.

Lu CX, Zheng BW, Bai B, et al. Effect of omeprazole on plasma concentration and adverse reactions of capecitabine in patients with colon cancer. Zhonghua Zhong Liu Za Zhi. 2019;41(9):708–11. https://doi.org/10.3760/cma.j.issn.0253-3766.2019.09.012.CrossRefPubMed

12.

Wong GG, Ha V, Chu MP, Dersch-Mills D, et al. Effects of proton pump inhibitors on FOLFOX and CapeOx regimens in colorectal cancer. Clin Colorectal Cancer. 2019;18(1):72–9. https://doi.org/10.1016/j.clcc.2018.11.001.CrossRefPubMed

13.

Rhinehart HE, Phillips MA, Wade N, Baran A. Evaluation of the clinical impact of concomitant acid suppression therapy in colorectal cancer patients treated with capecitabine monotherapy. J Oncol Pharm Pract. 2019;25(8):1839–45. https://doi.org/10.1177/1078155218818237.CrossRefPubMed

14.

Wang X, Liu C, Wang J, Fan Y, Wang Z, Wang Y. Proton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer. Oncotarget. 2017;8(35):58801–8. https://doi.org/10.18632/oncotarget.18522.CrossRefPubMedPubMedCentral

15.

Zhang JL, Liu M, Yang Q, Lin SY, Shan HB, Wang HY, Xu GL. Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer. World J Gastroenterol. 2017;23(14):2575–84. https://doi.org/10.3748/wjg.v23.i14.2575.CrossRefPubMedPubMedCentral

16.

Sun J, Ilich AI, Kim CA, Chu MP, Wong GG, Ghosh S, Danilak M, Mulder KE, Spratlin JL, Chambers CR, Sawyer MB. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer. 2016;15(3):257–63. https://doi.org/10.1016/j.clcc.2015.12.008.CrossRefPubMed

17.

Yang JY, Sanoff HK, Sandler RS, Stürmer T, Funk MJ, Lund JL. Does proton-pump inhibitor use diminish capecitabine efficacy in advanced cancer patients? Pharmacoepidemiology Drug Safety. 2017;26(Supplement 2):222–3.

18.

Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2017;3(6):767–73. https://doi.org/10.1001/jamaoncol.2016.3358. (Erratum. In: JAMA Oncol. 2017 Dec 1;3(12):1742).CrossRefPubMed

19.

Roberto M, Arrivi G, Milano A, et al. Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours. Ann Oncol. 2019;30(Supplement 4):AA43–AA44.CrossRef

20.

Sekido M, Fujita KI, Kubota Y, et al. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil. Cancer Chemother Pharmacol. 2019;83(6):1127–35. https://doi.org/10.1007/s00280-019-03837-y.CrossRefPubMed

21.

Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol. 1999;43:309–15.CrossRef

22.

Chen M, Zou X, Luo H, et al. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. Cell Biol Int. 2009;33(9):1008–199. https://doi.org/10.1016/j.cellbi.2009.05.004.CrossRefPubMed

23.

Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271–85. https://doi.org/10.1038/nrc.2017.13.CrossRefPubMed

24.

Lehouritis P, Cummins J, Stanton M, et al. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015;5:14554. https://doi.org/10.1038/srep14554.CrossRefPubMedPubMedCentral

25.

Lanas A. We are using too many PPIs, and we need to stop: a European perspective. Am J Gastroenterol. 2016;111(8):1085–6. https://doi.org/10.1038/ajg.2016.166.CrossRefPubMed

26.

Van Vliet EP, Otten HJ, Rudolphus A, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20:608–12.CrossRef

Title: Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review
Authors: D. Viñal
N. Rodriguez-Salas
P. Perez-Wert
O. Higuera
I. Ghanem
J. Feliu
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: Omeprazole
Rabeprazole
Proton Pump Inhibitors
Colorectal Cancer
Colorectal Cancer
Published in: Clinical and Translational Oncology / Issue 8/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02254-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2020

Expressions of IL-17 and TNF-α in patients with Hashimoto’s disease combined with thyroid cancer before and after surgery and their relationship with prognosis

Survey of treatment recommendations for elderly patients with glioblastoma

Adjuvant therapy for true ampullary cancer: a systematic review

Is one brachytherapy fraction of 7 Gy similar to more fractions after external beam irradiation in postoperative endometrial carcinoma?

Transoral robotic surgery for squamous cell carcinoma of the oropharynx in a primarily human papillomavirus-negative patient population

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer